Key Takeaway: Zeto has partnered with Firefly Neuroscience to distribute its FDA-cleared EEG headsets, WR19 and Zeto ONE. Firefly will serve as a non-exclusive distributor, enhancing the reach of these devices. The partnership also involves integrating Firefly's Brain Network Analytics technology with Zeto's EEG platforms, which are already utilized in over 200 healthcare facilities across the U.S.
Price reaction · baseline $3.78 (2024-09-12T14:05:00.000Z) · hit during market hours · clean, no other AIFF news in the window
day 0 close · peak
-2.6%
Market Sentiment Analysis
POSITIVE FACTORS
Collaboration enhances distribution of FDA-cleared EEG devices.
Integration of advanced analytics technology with EEG platforms.
Products are already in use in over 200 hospitals.
Full Press Release Details
AI company Zeto has teamed up with Firefly Neuroscience to distribute Zeto’s US Food and Drug Administration (FDA)-cleared electroencephalogram (EEG) headsets.
Under the deal, Firefly is now a non-exclusive distributor for Zeto’s pair of EEG headsets, dubbed WR19 and Zeto ONE. The collaboration also includes the integration of Firefly’s proprietary Brain Network Analytics (BNA) technology with the EEG platforms, which Firefly say are used in more than 200 hospitals and neurology offices across the US.
Read Article
Frequently Asked Questions
What is the purpose of the partnership between Firefly and Zeto?
The partnership aims to distribute Zeto's FDA-cleared EEG headsets.
What are the names of the EEG headsets involved?
The EEG headsets are called WR19 and Zeto ONE.
How many hospitals use these EEG devices?
The EEG platforms are used in over 200 hospitals and neurology offices.
What technology is integrated with Zeto's EEG platforms?
Firefly's proprietary Brain Network Analytics technology is integrated.